Lerdelimumab
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | TGF beta 2 |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
|
It was being developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.[2]
References
- "Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody". Drugs in R&D. 3 (2): 106–108. 1 February 2002. doi:10.2165/00126839-200203020-00006. PMID 12001808.
- "CAT abandons Trabio after second clinical trial failure. | Goliath Business News". Goliath.ecnext.com. 2005-03-28. Retrieved 2010-05-12.
Intracellular (initiation) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (reception) |
| ||||||||||||||
Extracellular |
|
TGFβ receptor superfamily modulators | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Type I |
| ||||||||||||||
Type II |
| ||||||||||||||
Type III |
| ||||||||||||||
Unsorted |
| ||||||||||||||
|
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.